HGH Fragment 176-191
HGH Fragment 176-191 is an isolated, C-terminal snippet of the human Growth Hormone molecule, definitively engineered to isolate hGH's profound fat-burning capability. Essentially a concentrated lipolytic engine, it entirely strips away the growth-promoting and diabetogenic components of the parent hormone. Clinically and athletically favored over full-sequence hGH, it rapidly forces visceral and subcutaneous adipocytes to release stored triglycerides into the bloodstream, achieving dramatic fat reduction without causing insulin resistance, organomegaly, or unwanted bone growth.
Quick Stats
Scientific Data
Mechanism of Action
HGH Fragment 176-191 is a truncated analog of human growth hormone consisting of amino acids 176-191 from the C-terminal region. This specific fragment retains the fat-burning activity of HGH without the growth-promoting, diabetogenic, or IGF-1-raising effects.
The fragment stimulates lipolysis (fat breakdown) by mimicking the way natural growth hormone regulates fat metabolism through the beta-3 adrenergic receptor. It also inhibits lipogenesis (new fat formation). Unlike exogenous HGH, it does not compete with human growth hormone receptors and does not induce insulin resistance, making it metabolically safer for dedicated fat-loss protocols.
Source: PMID: 11713213
Background & History
HGH Fragment 176-191 is the C-terminal fragment of human growth hormone. Originally identified by researchers studying which region of hGH drives lipolysis, Frank and colleagues showed the 176-191 region contains the lipolytic activity while the 1-43 region drives the diabetogenic IGF-1 effects. This makes Fragment 176-191 a selective fat-burning peptide without GH's anabolic or glucose-altering effects. Related to AOD-9604 (which adds a tyrosine for stability), it remains a popular research peptide for body composition.
Research Use Cases
- ✓Selective lipolysis without blood glucose effects
- ✓Body recomposition: fat reduction preserving muscle
- ✓Obese or insulin-resistant individuals seeking GH-like fat loss
Dosing Protocol
| Typical Dose | 250-500 mcg/day |
| Frequency | 1-2× daily (fasted) |
| Half-Life | ~30 minutes |
| Common Vial Sizes | 2 mg, 5 mg |
Dosing Protocols
Standard Fat Loss
Advanced Protocol
Body-Weight Dosing Reference
Estimated doses extrapolated from the published research range of 250–500 mcg/day (referenced to 70 kg / 154 lb). These are approximations — consult a qualified healthcare provider for personalised guidance.
| Weight | Low Dose | Target Dose | High Dose |
|---|---|---|---|
| 120 lb(54 kg) | 193 mcg | 289 mcg | 386 mcg |
| 140 lb(63 kg) | 225 mcg | 338 mcg | 450 mcg |
| 160 lb(73 kg) | 261 mcg | 391 mcg | 521 mcg |
| 180 lb(82 kg) | 293 mcg | 439 mcg | 586 mcg |
| 200 lb(91 kg) | 325 mcg | 488 mcg | 650 mcg |
| 220 lb(100 kg) | 357 mcg | 536 mcg | 714 mcg |
| 250 lb(113 kg) | 404 mcg | 605 mcg | 807 mcg |
💉 For exact syringe units based on your vial concentration, use the HGH Fragment 176-191 Reconstitution Calculator →
Administration
Expected Timeline
Who Is It For?
Fat Loss
HighSpecifically targets fat metabolism without the side effects of full HGH. Best for stubborn and visceral fat reduction.
Metabolic Health
ModerateDoes not affect blood glucose or IGF-1 levels — suitable for those who cannot use full GH.
Reconstitution Example
Safety & Considerations
Research peptide. Does not induce insulin resistance or affect IGF-1. No significant systemic side effects reported. Must be administered in a fasted state for optimal lipolytic effect.
Regulatory & Legal Status
Not currently on the WADA 2026 Prohibited List. Policies may change — verify before competition.
Research Chemical
US Compounding: Not eligible / not available
⚠️ This information is for educational purposes only and may not reflect the most current regulatory updates. Always verify with official FDA, WADA, and jurisdiction-specific sources before use.
Interactions & Contraindications
Does not elevate IGF-1 or affect glucose — advantageous in metabolic patients. Minimal documented drug interactions. Lower potency for fat loss than full GH — dose accordingly.
Synergies & Common Stacks
Fragment handles fat burning; CJC-1295 drives GH's anabolic and recovery benefits. Splits GH's two main effects for targeted outcomes.
Same rationale — Ipamorelin provides clean GH elevation for recovery; Fragment 176-191 handles the fat loss component without glycemic impact.
Dosing Quick Reference
Frequently Asked Questions
Is HGH Fragment 176-191 the same as AOD-9604?▼
Must I inject Frag 176-191 fasted?▼
References
- Heffernan M et al. “"The lipolytic effect of a human growth hormone fragment".” J Endocrinol (2001). PMID: 11182753
📚 Related Articles
Looking for a trusted source? See our recommended suppliers →
Independently tested · COA-verified · Save 10% with our exclusive code